Medicare Drug Cost Sharing Shifts Drive Higher Patient Expenses
Medicare beneficiaries face higher costs as Part D plans shift from fixed co-pays to coinsurance for expensive Tier 3 drugs, raising out-of-pocket expenses significantly.
Medicare Part D Stand-Alone PDPs Crucial in Rural Areas Amid Market Changes
Medicare Part D stand-alone prescription drug plans serve a majority of rural Medicare beneficiaries, with premium stabilization efforts influencing plan availability and affordability in 2025 and beyond.
Medicare Advantage Market Growth Slows in Early 2025, Reports MFA
Mark Farrah Associates reports a slowdown in Medicare Advantage market growth with detailed enrollment and market share data for early 2025. Key tools aid insurers in competitive analysis post-Open Enrollment Period.
CMS Raises 2026 Medicare Advantage Reimbursement, Adjusts Drug Coverage Policies
CMS increases 2026 Medicare Advantage reimbursement rates to 5.06%, easing insurer pressures while adjusting policies on obesity drug coverage and billing practices.
Trump Executive Order on Drug Pricing Targets Medicare, 340B Reimbursements
Summary of Trump's executive order directing HHS to reduce prescription drug costs, focusing on Medicare reimbursement for 340B drugs, IRA drug pricing provisions, and CMS premium stabilization efforts.